Therapeutic methods relating to human carbamyl phosphate synthetase I polymorphism
AssigneeVanderbilt University
InventorsMarshall L. Summar, Brian W. Christman
Life of this patent
Estimating the term…
Abstract
Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.
Claims15
A method of treating or preventing sub-optimal urea cycle function in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a nitric oxide precursor, whereby treatment or prevention of sub-optimal urea cycle function is accomplished.
A method of treating or preventing bone marrow transplant toxicity in a subject undergoing bone marrow transplant, the method comprising administering to the subject a therapeutically effective amount of a nitric oxide precursor, whereby bone marrow transplant toxicity is treated or prevented in the subject.
Dependencies are inferred from the claim text.